| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0079-6123(01)32111-8 |
| P698 | PubMed publication ID | 11545029 |
| P2093 | author name string | Sillevis Smitt PA | |
| Nanda D | |||
| Driesse MJ | |||
| P2860 | cites work | The human TRIDENT/HFH-11/FKHL16 gene: structure, localization, and promoter characterization | Q24322793 |
| Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR | Q27620424 | ||
| Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease | Q28143064 | ||
| Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment | Q29615852 | ||
| Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group | Q30584392 | ||
| A system for the propagation of adenoviral vectors with genetically modified receptor specificities | Q30630915 | ||
| Brain tumor survival: results from the National Cancer Data Base | Q31932199 | ||
| Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization | Q33606829 | ||
| An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism | Q33786008 | ||
| Studies on the use of viruses in the treatment of carcinoma of the cervix | Q34240325 | ||
| An adenovirus mutant that replicates selectively in p53-deficient human tumor cells | Q34399844 | ||
| Expression of heterologous sequences in adenoviral vectors | Q34410472 | ||
| Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo | Q35152561 | ||
| Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. | Q35870225 | ||
| Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization | Q40780995 | ||
| Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials | Q40790899 | ||
| Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae | Q40917425 | ||
| A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma | Q40938714 | ||
| Targeted gene delivery by tropism-modified adenoviral vectors | Q41152060 | ||
| Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects | Q41710263 | ||
| Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. | Q41722852 | ||
| Interleukin-1 mediates a rapid inflammatory response after injection of adenoviral vectors into the brain. | Q42536199 | ||
| In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors | Q42818740 | ||
| The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats | Q42835030 | ||
| Reoperation for recurrent glioblastoma and anaplastic astrocytoma | Q43595665 | ||
| Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer | Q43842247 | ||
| Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. | Q43866864 | ||
| Intracranial administration of adenovirus expressing HSV-TK in combination with ganciclovir produces a dose-dependent, self-limiting inflammatory response. | Q44678297 | ||
| Virus treatment questioned after gene therapy death | Q45746742 | ||
| Preclinical testing of recombinant adenoviral herpes simplex virus-thymidine kinase gene therapy for central nervous system malignancies | Q45761177 | ||
| Herpes simplex virus thymidine kinase gene therapy for rat malignant brain tumors | Q45768571 | ||
| The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication | Q45856424 | ||
| Intracerebral injection of adenovirus harboring the HSVtk gene combined with ganciclovir administration: toxicity study in nonhuman primates | Q45858203 | ||
| A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group | Q45862712 | ||
| T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. | Q45866838 | ||
| Intra-CSF administered recombinant adenovirus causes an immune response-mediated toxicity | Q45870681 | ||
| Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial. | Q45878724 | ||
| Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression | Q45881664 | ||
| Neurotoxicity of intracerebral injection of a replication-defective adenoviral vector in a semipermissive species (cotton rat). | Q45882064 | ||
| Irinotecan therapy in adults with recurrent or progressive malignant glioma | Q48207492 | ||
| Survival and functional status after resection of recurrent glioblastoma multiforme | Q48476773 | ||
| Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells | Q48587406 | ||
| Polarographic measurements of oxygen tension in human glioma and surrounding peritumoural brain tissue. | Q51419552 | ||
| Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. | Q54635100 | ||
| Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. | Q55485347 | ||
| Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. | Q55486820 | ||
| A Phase I/II Study of Herpes Simplex Virus Type 1 Thymidine Kinase “Suicide” Gene Therapy for Recurrent Glioblastoma | Q58659735 | ||
| Reports of adenovector "death" are greatly exaggerated | Q64380556 | ||
| Adenoviral-mediated thymidine kinase gene transfer into the primate brain followed by systemic ganciclovir: pathologic, radiologic, and molecular studies | Q64382810 | ||
| Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis | Q71660966 | ||
| P921 | main subject | suicide | Q10737 |
| Adenoviridae | Q193447 | ||
| gene therapy | Q213901 | ||
| P304 | page(s) | 699-710 | |
| P577 | publication date | 2001-01-01 | |
| P1433 | published in | Progress in Brain Research | Q15800382 |
| P1476 | title | Clinical trials of adenoviral-mediated suicide gene therapy of malignant gliomas | |
| P478 | volume | 132 |
| Q45127753 | AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study |
| Q36534930 | Frontiers in Suicide Gene Therapy of Cancer |
| Q35184733 | Gene therapy for neurological disease |
| Q35172534 | Growth-factor gene therapy for neurodegenerative disorders |
| Q73371191 | T-cell immune responses in the brain and their relevance for cerebral malignancies |
Search more.